SCYNEXIS Inc (SCYX) Receives Consensus Rating of “Buy” from Brokerages

Share on StockTwits

Shares of SCYNEXIS Inc (NASDAQ:SCYX) have earned an average rating of “Buy” from the ten analysts that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $5.29.

A number of brokerages have issued reports on SCYX. Maxim Group lowered their target price on SCYNEXIS from $6.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, October 16th. Zacks Investment Research cut SCYNEXIS from a “buy” rating to a “hold” rating in a report on Friday. ValuEngine raised SCYNEXIS from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. HC Wainwright set a $5.00 price target on SCYNEXIS and gave the company a “buy” rating in a research note on Tuesday, October 23rd. Finally, Brookline Capital Management reissued a “buy” rating on shares of SCYNEXIS in a research note on Friday, January 4th.

SCYX traded up $0.18 on Monday, reaching $1.34. The stock had a trading volume of 3,152,070 shares, compared to its average volume of 1,961,073. SCYNEXIS has a fifty-two week low of $0.35 and a fifty-two week high of $2.15. The company has a quick ratio of 4.53, a current ratio of 4.53 and a debt-to-equity ratio of 0.27. The stock has a market cap of $57.28 million, a PE ratio of -1.33 and a beta of 2.28.

SCYNEXIS (NASDAQ:SCYX) last issued its earnings results on Tuesday, November 13th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.18. SCYNEXIS had a negative return on equity of 102.52% and a negative net margin of 8,592.97%. The business had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.06 million. On average, equities research analysts expect that SCYNEXIS will post -0.51 EPS for the current year.

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new stake in shares of SCYNEXIS in the second quarter valued at about $190,000. Northern Trust Corp increased its stake in shares of SCYNEXIS by 132.7% in the second quarter. Northern Trust Corp now owns 116,079 shares of the company’s stock valued at $190,000 after buying an additional 66,193 shares during the period. BlackRock Inc. increased its stake in shares of SCYNEXIS by 61.5% in the second quarter. BlackRock Inc. now owns 180,751 shares of the company’s stock valued at $296,000 after buying an additional 68,830 shares during the period. Private Advisor Group LLC acquired a new stake in shares of SCYNEXIS in the third quarter valued at about $240,000. Finally, Stonepine Capital Management LLC acquired a new stake in shares of SCYNEXIS in the third quarter valued at about $539,000. 41.53% of the stock is owned by institutional investors.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.

Featured Story: Understanding Specialty Certificates of Deposit

Analyst Recommendations for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Chatham Lodging Trust  Receives Consensus Rating of “Hold” from Brokerages
Chatham Lodging Trust Receives Consensus Rating of “Hold” from Brokerages
SCYNEXIS Inc  Receives Consensus Rating of “Buy” from Brokerages
SCYNEXIS Inc Receives Consensus Rating of “Buy” from Brokerages
Ceragon Networks  Lowered to Hold at Zacks Investment Research
Ceragon Networks Lowered to Hold at Zacks Investment Research
Joint Ventures  Trading 32.7% Lower  This Week
Joint Ventures Trading 32.7% Lower This Week
Jibrel Network  Market Capitalization Achieves $5.22 Million
Jibrel Network Market Capitalization Achieves $5.22 Million
StoneMor Partners L.P.  Major Shareholder Acquires $56,971.20 in Stock
StoneMor Partners L.P. Major Shareholder Acquires $56,971.20 in Stock


Leave a Reply

 
© 2006-2019 Zolmax.